Exelixis

FDA Accepts Exelixis' NDA for Colorectal Cancer Combo, Boosting Valuation Focus

伊克力西斯

Exelixis's 15min chart triggers Bollinger Bands Narrowing and KDJ Death Cross.

Exelixis: Barclays Keeps Equal-Weight Rating, Raises PT to $44 from $41.

Exelixis's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing.

Exelixis:HC Wainwright Raises Buy Rating, PT to $52 from $52

Catalyst<ul> <li>Most analysts rate EXEL Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (3 bearish vs 1 bullish) in recent technical analysis.</li> <li>Fund flow trends are negative for medium, large, and extra-large orders despite positive inflows in small orders.</li></ul>

Key Factors

Exelixis' cabozantinib franchise generated $2.123 billion in preliminary U.S. net product revenues for fiscal 2025, leading to a $100 million increase in full-year revenue guidance. FDA accepted Exelixis' New Drug Application for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, supported by Phase 3 trial results.

EXEL News